How big is the Breast Cancer Liquid Biopsy Market?

The Breast Cancer Liquid Biopsy Market size is expected to reach USD 0.41 billion in 2024 and grow at a CAGR of 21.23% to reach USD 1.06 billion by 2029. Read More

What is the current Breast Cancer Liquid Biopsy Market size?

In 2024, the Breast Cancer Liquid Biopsy Market size is expected to reach USD 0.41 billion. Read More

Who are the key players in Breast Cancer Liquid Biopsy Market?

F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Johnson & Johnson (Janssen Diagnostics), Biocept Inc and Qiagen are the major companies operating in the Breast Cancer Liquid Biopsy Market. Read More

Which is the fastest growing region in Breast Cancer Liquid Biopsy Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Breast Cancer Liquid Biopsy Market?

In 2024, the North America accounts for the largest market share in Breast Cancer Liquid Biopsy Market. Read More

What years does this Breast Cancer Liquid Biopsy Market cover, and what was the market size in 2023?

In 2023, the Breast Cancer Liquid Biopsy Market size was estimated at USD 334.44 million. The report covers the Breast Cancer Liquid Biopsy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Breast Cancer Liquid Biopsy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Breast Cancer Liquid Biopsy Market Share

Statistics for the 2023 & 2024 Breast Cancer Liquid Biopsy market share, created by Mordor Intelligence™ Industry Reports. Breast Cancer Liquid Biopsy share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Breast Cancer Liquid Biopsy Industry

The breast cancer liquid biopsy market is slightly fragmented and competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies currently dominating the market are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc., Janssen Diagnostics, Biocept Inc., Guardant Health Inc., Myriad Genetics, Adaptive Biotechnologies, Epic Sciences, Fluxion Biosciences Inc., Biodesix, and Illumina Inc.